[1]胡德献　孙衍昶　冯基高　莫业和.CDCA7L在人脑胶质瘤组织中的表达及意义[J].中国临床神经外科杂志,2020,(12):834-837.[doi:10.13798/j.issn.1009-153X.2020.12.006]
　HU De-xian,SUN Yan-chang,FENG Ji-gao,et al.Expression of CDCA7L in human glioma tissues and its clinical significance[J].,2020,(12):834-837.[doi:10.13798/j.issn.1009-153X.2020.12.006]
点击复制

CDCA7L在人脑胶质瘤组织中的表达及意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年12期
页码:
834-837
栏目:
论著
出版日期:
2020-12-25

文章信息/Info

Title:
Expression of CDCA7L in human glioma tissues and its clinical significance
文章编号:
1009-153X（2020）12-0834-04
作者:
胡德献　孙衍昶　冯基高　莫业和
570311 海口，海南医学院第二附属医院神经外科（胡德献、孙衍昶、冯基高、莫业和）
Author(s):
HU De-xian;  SUN Yan-chang;  FENG Ji-gao;  MO Ye-he.
Department of Neurosurgery, The Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China
关键词:
胶质瘤; 细胞分裂周期相关7样蛋白; 基因表达; 生存预后
Keywords:
Glioma;  Cell division cycle-associated 7-like protein;  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2020.12.006
文献标志码:
A
摘要:
目的 探讨细胞分裂周期相关7样蛋白（CDCA7L）在胶质瘤组织中的表达及其与病人预后的关系。方法 免疫组织化学染色法检测2012年1月至2013年5月手术切除的112例胶质瘤组织和2018年1~12月颅脑损伤内减压术中切除的45例正常脑组织中CDCA7L的表达水平，根据染色情况将胶质瘤病人分为高表达组和低表达组。胶质瘤病人随访截止2019年6月，记录总生存期（OS）和无进展生存期（PFS）。结果 胶质瘤组织CDCA7L高表达率（66.96%，75/112）明显高于正常脑组织（17.78%，8/45；P<0.05）。高级别胶质瘤组织CDCA7L高表达率（79.41%，54/68）明显高于低级别胶质瘤（47.73%，21/44；P<0.05）。多因素Cox比例风险回归模型分析结果显示，CDCA7L高表达是胶质瘤病人OS和PFS较短的独立影响因素（P<0.05）。生存曲线分析显示，高表达组中位OS（21个月，四分位区间16~41个月）和中位PFS（18个月，四分位区间13~38个月）均明显低于低表达组[分别为60个月（48~65个月）和45个月（41~52个月）；P<0.05]。结论 胶质瘤组织CDCA7L呈高表达，而且与胶质瘤不良生存预后和肿瘤进展有关。
Abstract:
Objective To investigate the expression of cell division cycle associated 7-like protein (CDCA7L) in human glioma tissues and its relationship with patients’ prognosis. Methods The expression level of CDCA7L in human glioma tissues obtained from 112 patients with glioma who underwent microsurgery from January 2012 to May 2013 and in normal brain tissues obtained from 45 patients with traumatic brain injury who underwent decompression from January to December 2018 were detected by immunohistochemical staining. According to the staining, the glioma patients were divided into high expression group and low expression group. The follow-up of glioma patients ended in June 2019, and the overall survival (OS) and progression-free survival (PFS) were recorded. Results The high expression rate of CDCA7L in glioma tissues (66.96%, 75/112) was significantly higher than that (17.78%, 8/45) in normal brain tissues (P<0.05). The high expression rate of CDCA7L in high-grade glioma tissues (79.41%, 54/68) was significantly higher than that (47.73%, 21/44) in low-grade glioma tissues (P<0.05).The multivariate Cox proportional hazard regression model analysis showed that the high expression of CDCA7L was an independent risk factor for shorter OS and PFS in glioma patients (P<0.05). The OS and PFS in the low-expression group were significantly higher than those in the high-expression group (P<0.05). Conclusions The CDCA7L is highly expressed in glioma tissue. The high expression of CDCA7L is related to the poor survival prognosis and tumor progression of glioma patients.

参考文献/References:

[1] Davis ME. Epidemiology and overview of gliomas [J]. Semin Oncol Nurs, 2018, 34(5): 420-429.
[2] Gusyatiner O, Hegi ME. Glioma epigenetics: from subclas-sification to novel treatment options [J]. Semin Cancer Biol, 2018, 51: 50-58.
[3] Tian Y, Huang C, Zhang H, et al. CDCA7L promotes hepa-tocellular carcinoma progression by regulating the cell cycle [J]. Int J Oncol, 2013, 43(6): 2082-2090.
[4] Liu N, Wang Z, Liu D, et al. HOXC13-AS-miR-122-5p-SATB1-C-Myc feedback loop promotes migration, invasion and EMT process in glioma [J]. Onco Targets Ther, 2019, 12: 7165-7173.
[5] Shi H, Zhang S. Expression and prognostic role of orphan receptor GPR110 in glioma [J]. Biochem Biophys Res Commun, 2017, 491(2): 349-354.
[6] Johnson S, Stockmeier CA, Meyer JH, et al. The reduction of R1, a novel repressor protein for monoa mine oxidase A, in major depressive disorder [J]. Neuropsychopharmacolo-gy, 2011, 36(10): 2139-2148.
[7] 赵　冲，汪　强，武奋萍，等. CDCA7L在结肠癌患者组织标本中的表达及临床意义[J]. 肿瘤学杂志，2017，23（10）：885-889.
[8] 李泓漪，胡晓玲，徐恩伟，等. CDCA7基因在食管鳞癌细胞系中的表达及其对细胞增殖凋亡的影响[J]. 中国药物与临床，2017，17（4）：461-464.
[9] Ye L, Li F, Song Y, et al. Overexpression of CDCA7 predictspoor prognosis and induces EZH2-mediated progression of triple-negative breast cancer [J]. Int J Cancer, 2018, 143(10): 2602-2613.
[10] Tan Z, Chen K, Wu W, et al. Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression [J]. Thera-nostics, 2018, 8(18): 5143-5158.
[11] Cannuyer J, Van Tongelen A, Loriot A, et al. A gene expres-sion signature identifying transient DNMT1 depletion as a causal factor of cancer-germline gene activation in melano-ma [J]. Clin Epigenetics, 2015, 7: 114-121.
[12] Li N, Johnson DC. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression [J]. Nat Commun, 2016, 7: 1-9.
[13] 李　冉，张利通，许红旗. 胶质瘤组织中CD44V9的表达及临床意义[J]. 临床肿瘤学杂志，2019，24（3）：40-44.
[14] 梅喜平，郑　鲲，邵碧波，等. microRNA-211在脑胶质瘤中的表达及其与临床病理预后的关系[J]. 山西医科大学学报，2017，48（7）：711-714.
[15] Liu LQ, Feng LF, Nan CR, et al. CREB3L1 and PTN expre-ssions correlate with prognosis of brain glioma patients [J]. Biosci Rep, 2018, 38(3): 1-8.

相似文献/References:

[1]常英男　王　策　赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
　CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(12):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛　克　陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许　耿　路俊锋　杨　忠　施建斌　吴秋月　王　烨　庄冬晓　吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
　XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(12):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(12):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波　杨宇焦　张　逵　范润金　张　渊　杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
　YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(12):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚　成于思　王　辉　汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
　HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(12):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林　雨　张　恺　李　帅　杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明　徐成仕　王泽芬　曹长军　李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
　DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(12):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生　田道锋　张申起　陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
　PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(12):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯　驰　郭双毅　程龙海　罗　杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
　FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(12):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]

备注/Memo

备注/Memo:
基金项目：海南省医药卫生科研项目（1601320272A2002）通讯作者：莫业和，E-mail：hainan_fu2yuan@163.com
更新日期/Last Update: 2020-12-25